Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $17.25.

Several brokerages have recently commented on ENTA. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $6.65 on Tuesday. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The stock has a 50-day simple moving average of $6.21 and a 200-day simple moving average of $8.65. The firm has a market cap of $141.86 million, a P/E ratio of -1.34 and a beta of 0.48.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, equities research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly acquired 45,000 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the purchase, the chief executive officer now directly owns 846,638 shares of the company’s stock, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Enanta Pharmaceuticals by 34.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after buying an additional 49,050 shares in the last quarter. Barclays PLC lifted its position in shares of Enanta Pharmaceuticals by 294.2% during the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 20,478 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $122,000. Finally, Geode Capital Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.